Page 39 - CIBERSAM-2015-eng

Research Groups
Most relevant scientific articles
Ferres-coy a., GaloFre M., PIlar-cuellar F., VIdal r., Paz V., ruIz-Bronchal e. et al. Therapeutic antidepres- sant potential of a conjugated siRNA silencing the seroto- nin transporter after intranasal administration. Molecular Psychiatry. 2015.
sánchez c., asIn k.e., artIGas F.. Vortioxetine, a novel an- tidepressant with multimodal activity: Review of preclin- ical and clinical data. Pharmacology and Therapeutics. 2015;145:43-47.
rIGa M.s., BortolozzI a., caMPa l., artIGas F., celada P.. The serotonergic hallucinogen 5-methoxy-N,N-dimethyl- tryptamine disrupts cortical activity in a regionally-selec- tive manner via 5-HT1A and 5-HT2A receptors. Neurop- harmacology. 2015;101:370-378.
llado-PelFort l., troyano-rodríGuez e., Van den Munk- hoF h.e., cerVera-FerrI a., Jurado n., nunez-calVet M. et al. Phencyclidine-induced disruption of oscillatory ac- tivity in prefrontal cortex: Effects of antipsychotic drugs
JIMénez-sánchez l, castañé a, Pérez-caBallero l, GrI- Foll-escoda M, lóPez-GIl x, caMPa l et al. Activation of AMPA Receptors Mediates the Antidepressant Action of Deep Brain Stimulation of the Infralimbic Prefrontal Cor- tex.Cerebral cortex (New York, N.Y. : 1991). 2015.
Highlights
The group has led a total of 12 grants during 2015, including 1 EU grant (IMI-NEWMEDS, Grant 115008 ), 5 Spanish competitive grants (SAF2012-35183, IPT-2012-1208-300000, PI10/00290, PI12/00156 and RTC-2014-2812-1), 1 autonomous community grant (2014SGR798), 1 international grant (The Brain & Behavior Research Foundation Grant 20003), 3 contracts with pharmaceutical companies (H. Lund- beck A/S; nLife Therapeutics) and 1 grant support- ed by The Alicia Koplowitz Foundation. On the other hand, the group applied to the Proyectos Excelencia I+D+I 2015 Spanish government call, whose accept- ance has been notified in February 2016 (SAF2015- 68346-P). Additionally, one patent of 2013 has been updated in USA on July 20, 2015 (14/803,811) and another of 2011 has been submitted according to the PCT application procedure.
From the studies carried out during 2015, we high- light a) development of novel antidepressant strat- egies using RNAi, b) study of the mechanism of action of ketamine, as a fast-acting antidepressant drug, c) study of the mechanism of action of novel antidepressant drugs, such as vortioxetine, d) devel- opment of preclinical models of schizophrenia, and d) identification of thalamocortical circuits as thera- peutic targets in schizophrenia.
and receptor ligands. European Neuropsychopharmacol- ogy. 2015.
Overall, the group keep a solid reputation in the field of Neuropsychopharmacology, as shown by its high level of citations (h-index of the PI = 57, who has achieved 11.000 citations in 2015). Among the awards and distinctions received during 2015, the PI has received the ECNP Neuropsychopharmacology Award from the European College of Neuropsychop- harmacology. Prof. F. Artigas is the first Spanish scientist receiving this Award, which included the invitation to give a plenary lecture at the 28th ECNP Congress, held in August 2015 (Amsterdam).
Institution: Agencia Estatal Consejo Superior de Investigaciones Científicas
Contact: Instituto de Investigaciones Biomédicas · C/ Rosselló 161, 6a Planta. 08036 Barcelona E.mail: [email protected] · Website: http://www.iibb.csic.es
CIBERSAM I Annual report 2015 I 39